Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Tetralogy of Fallot
|
disease |
0.610 |
None
|
1.000 |
1 |
1 |
2002 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Neoplasms
|
group |
0.360 |
None
|
1.000 |
6 |
0 |
2009 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Malignant Neoplasms
|
group |
0.330 |
None
|
1.000 |
3 |
0 |
2011 |
2017 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Ventricular Septal Defects
|
group |
0.310 |
None
|
1.000 |
1 |
0 |
2013 |
2013 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Heart Septal Defects
|
group |
0.310 |
None
|
1.000 |
1 |
0 |
2005 |
2005 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Congenital Abnormality
|
group |
0.080 |
None
|
1.000 |
8 |
0 |
2005 |
2020 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Coronary heart disease
|
disease |
0.080 |
None
|
1.000 |
8 |
1 |
2005 |
2020 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Congenital heart disease
|
group |
0.070 |
None
|
1.000 |
7 |
1 |
2011 |
2020 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Malignant neoplasm of breast
|
disease |
0.060 |
None
|
1.000 |
6 |
0 |
2009 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Breast Carcinoma
|
disease |
0.060 |
None
|
1.000 |
6 |
0 |
2009 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Congenital Heart Defects
|
group |
0.050 |
None
|
1.000 |
5 |
0 |
2005 |
2020 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Mammary Neoplasms
|
group |
0.040 |
None
|
1.000 |
4 |
0 |
2009 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Agenesis
|
disease |
0.030 |
None
|
1.000 |
3 |
0 |
2005 |
2012 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Cardiac defects
|
group |
0.030 |
None
|
1.000 |
3 |
0 |
2005 |
2019 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Leukemia, Myelocytic, Acute
|
disease |
0.030 |
None
|
1.000 |
3 |
0 |
2015 |
2019 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Secondary malignant neoplasm of bone
|
disease |
0.020 |
None
|
1.000 |
2 |
0 |
2010 |
2016 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Neoplasm Metastasis
|
phenotype |
0.020 |
None
|
0.500 |
2 |
0 |
2016 |
2018 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Primary malignant neoplasm
|
group |
0.020 |
None
|
1.000 |
2 |
0 |
2011 |
2015 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Stomach Carcinoma
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2017 |
2017 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Carcinogenesis
|
phenotype |
0.010 |
None
|
1.000 |
1 |
0 |
2007 |
2007 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Colon Carcinoma
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2007 |
2007 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Malignant Fibrous Histiocytoma
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2019 |
2019 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Secondary malignant neoplasm of lymph node
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2016 |
2016 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Muscular ventricular septum defect
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2005 |
2005 |
Entrez Id: |
10370 |
Gene Symbol: |
CITED2 |
CITED2
|
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2
|
0.576 |
0.654 |
0.76 |
Prostate carcinoma
|
disease |
0.010 |
None
|
1.000 |
1 |
0 |
2018 |
2018 |